2024-02-06 15:00:00
Prodigy Biotech Enters into Collaboration Agreement with Leading Cancer Center to Promote PRODUCTS THAT IMPROVE OUTCOMES IN ALLOGENIC HEMATOPOETIC STEM CELL TRANSPLANTATION PATIENTS
- Prodigy is the first company to join the MSK Therapeutics Accelerator program. The launch of the accelerator program was announced at the MSK Life Sciences Innovation Summit in New York on January 26, 2024.
- Prodigy and Memorial Sloan Kettering Cancer Center (MSK) will collaborate to develop a product that targets Enterococcus sp. works to treat microbial dysbiosis in patients undergoing allogeneic hematopoietic stem cell transplantation. The product will build on Prodigy’s polyclonal immunoglobulin Y (IgY) technology, which has promising preclinical data in models of alcoholic liver disease.
West Chester, Pennsylvania, USA. February 6, 2024 – Prodigy and MSK have entered into a research collaboration agreement under the MSK Therapeutics Accelerator program to evaluate Prodigy’s product candidate to improve outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HCT). The MSK Therapeutics Accelerator project is led by Dr. Jonathan Peled (MD/Ph.D), specialist at MSK, led.
Through his groundbreaking research activities, Dr. Peled and his team at MSK have made significant progress in identifying the influence of the microbiome on the outcomes of patients undergoing allo-HCT. The work of Dr. Peled showed that patients undergoing allo-HCT may have an increased incidence of enterococci, resulting in worse overall survival and higher mortality associated with graft-versus-host disease (GVHD). has. Dr. Peled has previously demonstrated in preclinical models that restoring the original gut microbiome has a significant impact in reducing disease severity.
This collaboration will use Prodigy’s antibodies to neutralize Enterococcus sp. evaluated in preclinical GvHD models and product candidates are being developed to initiate the clinical development phase. Prodigy is also looking forward to Dr. Peled will provide support in establishing and joining the Scientific Advisory Board (SAB) for allo-HCT.
In addition to supporting research, MSK will provide expertise and institutional resources through the MSK Therapeutics Accelerator to assist in the development of a drug candidate for patients undergoing allogeneic hematopoietic stem cell transplantation. The MSK Therapeutics Accelerator Program is a collaboration program between MSK and technology and pharmaceutical companies to promote novel therapeutics in all phases of drug development. The program brings together innovative healthcare companies with MSK’s clinical and scientific experts to collaborate on groundbreaking developments that can have a meaningful impact on cancer treatment and care.
Satish Chandran, CEO of Prodigy, said: “We are pleased to partner with the MSK Therapeutics accelerator program and Dr. Peled to work together to develop a product(s) for patients undergoing allo-HCT. Given the significant morbidity and mortality associated with the disease, we are all called upon to find solutions that have the potential to save lives and enable these patients to return to a normal life. We are very pleased with the robust preclinical proof-of-concept data for our alcoholic hepatitis product PROD-AH-001 (Hepatology, 2023), which is currently eligible for an Investigational New Drug (IND) application with the FDA is being prepared.”
Dr. Jonathan Peled from MSK explained: “Patients treated by allo-HCT experience the most extreme microbiome damage seen in a clinical setting. There is an urgent need to develop approaches to mitigate this and prevent the spread of potentially pathogenic bacteria. We expect that limiting the spread of Enterococcus within the digestive tract will prevent bloodstream infections caused by this bacterium and potentially also improve GVHD.”
Dr. Chandran presented information about this important new collaboration on January 26, 2024 at the MSK Life Sciences Innovation Summit in New York.
About allogeneic hematopoietic stem cell transplants (allo-HCTs):
Allo-HCTs can cure malignancies, but are associated with a high number of complications and increased mortality. Allo-HCT can lead to various complications affecting different organs due to the intensive conditioning therapy and the introduction of foreign immune cells. A major problem after allo-HCT is graft-versus-host disease (GvHD), in which the donor’s immune cells attack the recipient’s organism, which is a major cause of morbidity and treatment-related mortality in this patient population. There is a clear need for therapies that make it possible to improve outcomes in patients with allogeneic hematopoietic stem cell transplantation.
About Prodigy Biotech, Inc.:
Prodigy Biotech is a privately held pharmaceutical company focused on developing products using its polyclonal immunoglobulin Y technology to target the microbiome while avoiding harmful effects on commensal microflora. The versatility of avian antibodies (IgY) confers pathogen-specific neutralization capabilities not only to bacteria, but also to viruses, fungi, endotoxins, and even human-secreted proteins such as cytokines and chemokines. A non-target approach and strategic collaboration with leading microbiome researchers have allowed Prodigy to build a diverse product pipeline ranging from modulating the gut microbiome in alcoholic liver disease (ALD) to modulating the lung microbiome in chronic obstructive pulmonary disease (COPD).
Notes Regarding Forward-Looking Statements:
This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. In some cases we may use terms such as “predicts”, “believes”, “potential”, “proposed”, “continue”, “estimates”, “anticipates”, “expects”, “plans”, “intends”, “may” , “could”, “may”, “will”, “should” or other expressions that involve uncertainty about future events or results to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that could cause actual events or results to differ materially from our current expectations. Any forward-looking statements we make in this press release are based solely on our beliefs as of the date of this press release. Except as required by law, we undertake no obligation to update any forward-looking statements contained in this press release, whether as a result of new information, future events or otherwise, after the date hereof.
Contact person at Prodigy Biotech:
Satish Chandran
Chief Executive Officer
[email protected]
https://www.prodigybiotech.com
#PRODIGY #BIOTECH #ENTERS #COOPERATION #AGREEMENT #LEADING #CANCER #CENTER